ID   LNCaP-Pro1
AC   CVCL_L164
DR   cancercelllines; CVCL_L164
DR   Wikidata; Q54902846
RX   PubMed=9816342;
CC   Population: Caucasian.
CC   Sequence variation: Mutation; HGNC; 644; AR; Simple; p.Thr878Ala (c.2632A>G); ClinVar=VCV000009831; Zygosity=Hemizygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 7010; MEN1; Simple; p.Tyr318Ter (c.954T>G) (p.Tyr313Ter, c.939T>A); ClinVar=VCV000439894; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8979; PIK3R1; Simple; p.Arg639Ter (c.1915C>T); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Lys6Argfs*4 (c.17_18delAA); ClinVar=VCV000231649; Zygosity=Unspecified (from parent cell line).
CC   Derived from site: Metastatic; Left supraclavicular lymph node; UBERON=UBERON_8480056.
DI   NCIt; C4863; Prostate carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0395 ! LNCaP
SX   Male
AG   50Y
CA   Cancer cell line
DT   Created: 06-05-13; Last updated: 05-10-23; Version: 16
//
RX   PubMed=9816342;
RA   Pettaway C.A., Pathak S., Greene G., Ramirez E., Wilson M.R.,
RA   Killion J.J., Fidler I.J.;
RT   "Selection of highly metastatic variants of different human prostatic
RT   carcinomas using orthotopic implantation in nude mice.";
RL   Clin. Cancer Res. 2:1627-1636(1996).
//